1. Home
  2. SSL vs TGTX Comparison

SSL vs TGTX Comparison

Compare SSL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sasol Ltd.

SSL

Sasol Ltd.

HOLD

Current Price

$13.51

Market Cap

5.6B

Sector

Energy

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$39.46

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSL
TGTX
Founded
1950
1993
Country
South Africa
United States
Employees
27411
399
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.0B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
SSL
TGTX
Price
$13.51
$39.46
Analyst Decision
Sell
Strong Buy
Analyst Count
1
5
Target Price
N/A
$49.80
AVG Volume (30 Days)
1.5M
2.3M
Earning Date
04-24-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.12
Revenue
N/A
$2,785,000.00
Revenue This Year
$3.79
$49.08
Revenue Next Year
$4.39
$26.69
P/E Ratio
$13.51
$340.88
Revenue Growth
N/A
N/A
52 Week Low
$3.90
$25.37
52 Week High
$14.37
$44.65

Technical Indicators

Market Signals
Indicator
SSL
TGTX
Relative Strength Index (RSI) 56.03 56.82
Support Level $11.82 $33.05
Resistance Level $13.68 $44.65
Average True Range (ATR) 0.33 1.94
MACD -0.09 0.16
Stochastic Oscillator 57.66 54.82

Price Performance

Historical Comparison
SSL
TGTX

About SSL Sasol Ltd.

Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.

Share on Social Networks: